Search research articles
Contact Us
Filters
Showing results (1-10 of 47) with videos related to
Page
of 5
Sort By:
Canadian Family Physician Medecin De Famille Canadien
|
November 16, 2013
Is evidence-based medicine overrated in family medicine?: No
Michel Labrecque, Michel Cauchon
Canadian Family Physician Medecin De Famille Canadien
|
November 16, 2013
Rebuttal: Is evidence-based medicine overrated in family medicine?: No
Michel Labrecque, Michel Cauchon
Canadian Family Physician Medecin De Famille Canadien
|
September 18, 2007
Should Canadians be offered systematic prostate cancer screening? No
Michel Labrecque, France Légaré, Michel Cauchon
Canadian Family Physician Medecin De Famille Canadien
|
September 18, 2007
Rebuttal: Should Canadians be offered systematic prostate cancer screening? NO
Michel Labrecque, France Légaré, Michel Cauchon
La Revue De Medecine Interne
|
July 18, 2020
[Among patients with stable coronary disease and moderate or severe ischemia, does coronary angiography and revascularization when possible plus optimal medical treatment result in better clinical outcomes compared with optimal medical therapy alone?]
Luc Lanthier, Gabriel Huard, Marc-Émile Plourde, et al.
La Revue De Medecine Interne
|
January 28, 2026
[In patients at high cardiovascular risk, with atherosclerosis or diabetes, but without a history of myocardial infarction or stroke, does treatment with evolocumab reduce major cardiovascular events compared to placebo, while being safe?]
Luc Lanthier, Alexandre Mutchmore, Marc-Émile Plourde, et al.
La Revue De Medecine Interne
|
November 20, 2024
[In patients with heart failure with preserved or mildly reduced ejection fraction, is finerenone effective in reducing a composite of heart failure exacerbation and cardiovascular death compared to placebo, and is it safe?]
Luc Lanthier, Alexandre Mutchmore, Marc-Émile Plourde, et al.
La Revue De Medecine Interne
|
December 18, 2024
[In patients with obesity and moderate to severe obstructive sleep apnea, is tirzepatide effective in reducing the apnea-hypopnea index compared to placebo, and is it safe?]
Alexandre Mutchmore, Michel Cauchon, Marc-Émile Plourde, et al.
La Revue De Medecine Interne
|
August 12, 2024
[Among patients with type 2 diabetes and chronic kidney disease, does semaglutide prevent end-stage renal disease, significant loss of kidney function, or death from renal or cardiovascular causes compared to placebo, and is it safe?]
Luc Lanthier, Alexandre Mutchmore, Marc-Émile Plourde, et al.
La Revue De Medecine Interne
|
July 22, 2022
[In pregnant women with mild chronic hypertension, does a treatment strategy using a treatment target<140/90mmHg compared to watchful waiting unless BP>160/105mmHg reduce the incidence of maternal and perinatal complications while being safe?]
Luc Lanthier, Nadine Sauvé, Marc-Émile Plourde, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 47) with videos related to
Sort By:
Page
of 5
Canadian Family Physician Medecin De Famille Canadien
|
November 16, 2013
Is evidence-based medicine overrated in family medicine?: No
Michel Labrecque, Michel Cauchon
Canadian Family Physician Medecin De Famille Canadien
|
November 16, 2013
Rebuttal: Is evidence-based medicine overrated in family medicine?: No
Michel Labrecque, Michel Cauchon
Canadian Family Physician Medecin De Famille Canadien
|
September 18, 2007
Should Canadians be offered systematic prostate cancer screening? No
Michel Labrecque, France Légaré, Michel Cauchon
Canadian Family Physician Medecin De Famille Canadien
|
September 18, 2007
Rebuttal: Should Canadians be offered systematic prostate cancer screening? NO
Michel Labrecque, France Légaré, Michel Cauchon
La Revue De Medecine Interne
|
July 18, 2020
[Among patients with stable coronary disease and moderate or severe ischemia, does coronary angiography and revascularization when possible plus optimal medical treatment result in better clinical outcomes compared with optimal medical therapy alone?]
Luc Lanthier, Gabriel Huard, Marc-Émile Plourde, et al.
La Revue De Medecine Interne
|
January 28, 2026
[In patients at high cardiovascular risk, with atherosclerosis or diabetes, but without a history of myocardial infarction or stroke, does treatment with evolocumab reduce major cardiovascular events compared to placebo, while being safe?]
Luc Lanthier, Alexandre Mutchmore, Marc-Émile Plourde, et al.
La Revue De Medecine Interne
|
November 20, 2024
[In patients with heart failure with preserved or mildly reduced ejection fraction, is finerenone effective in reducing a composite of heart failure exacerbation and cardiovascular death compared to placebo, and is it safe?]
Luc Lanthier, Alexandre Mutchmore, Marc-Émile Plourde, et al.
La Revue De Medecine Interne
|
December 18, 2024
[In patients with obesity and moderate to severe obstructive sleep apnea, is tirzepatide effective in reducing the apnea-hypopnea index compared to placebo, and is it safe?]
Alexandre Mutchmore, Michel Cauchon, Marc-Émile Plourde, et al.
La Revue De Medecine Interne
|
August 12, 2024
[Among patients with type 2 diabetes and chronic kidney disease, does semaglutide prevent end-stage renal disease, significant loss of kidney function, or death from renal or cardiovascular causes compared to placebo, and is it safe?]
Luc Lanthier, Alexandre Mutchmore, Marc-Émile Plourde, et al.
La Revue De Medecine Interne
|
July 22, 2022
[In pregnant women with mild chronic hypertension, does a treatment strategy using a treatment target<140/90mmHg compared to watchful waiting unless BP>160/105mmHg reduce the incidence of maternal and perinatal complications while being safe?]
Luc Lanthier, Nadine Sauvé, Marc-Émile Plourde, et al.
Page
of 5